Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896181 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00896181: Completed Phase 2 study, sponsored by Stanford University.
NCT00896181 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896181, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving combination chemotherapy together with radiation therapy may kill more tumor cells.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG docetaxel
- DRUG fluorouracil
- RADIATION 3-dimensional conformal radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-12-10 |
| Est. Completion | 2020-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896181
The ClinicalTrials.gov registry entry for NCT00896181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00896181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896181 about?
NCT00896181 is a clinical study titled "Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)". This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin,...
What is the current status of trial NCT00896181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-12-10. Estimated completion is 2020-12.
What interventions are being tested in trial NCT00896181?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), docetaxel (DRUG), fluorouracil (DRUG), 3-dimensional conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00896181?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.